Articles tagged with Metastasis
Researchers found that bacteria in tumors play a critical role in promoting cancer cell metastasis by modulating the cellular actin network and enhancing cell survival. This discovery could lead to new targets for preventing metastasis, potentially improving cancer treatment outcomes.
Researchers have identified a gene mutation in ARID2 that signals the development of aggressively metastatic melanoma. The study suggests patients with this mutation may require different treatment approaches to manage their cancer effectively. Further research is underway to refine this understanding and improve patient outcomes.
A research team at LKS Faculty of Medicine, The University of Hong Kong, has discovered a new molecular pathway governing melanoma angiogenesis and metastasis. They found that the expression of DEPDC1B is significantly associated with poor patient survival and positively correlated with melanoma growth and metastasis.
The American Association for Cancer Research (AACR) has announced the recipients of its 2022 Scientific Achievement Awards and Lectureships, recognizing Tony Hunter, Christina Curtis, John E. Dick, Kevan M. Shokat, and Lee M. Ellis for their groundbreaking contributions to cancer research.
A study by MedUni Vienna reveals that mutations in the KMT2C protein lead to increased cell division, driving metastatic prostate cancer. This discovery may enable early diagnosis through a blood test and treatment with MYC inhibitors.
A recent study from Memorial Sloan Kettering Cancer Center reveals that a specific genetic program, positional identity, determines the location of acral melanoma. The research, led by Dr. Richard White, found that this program is conserved throughout evolution and explains why certain mutations lead to cancer in specific areas. This b...
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Researchers have identified two glucose transporters that disrupt the energy supply to invading worm cells and stop them in their tracks. By deactivating these genes, glucose and ATP levels dropped, and worm cells stalled their spread. This discovery could lead to new ways to cut off cancer cells' fuel lines and prevent metastasis.
Researchers Miao-Ping Chien and Daan Brinks have developed a method to detect aggressive cancer cells, which can help identify the genetic profile of individual cells and develop targeted medicines. This breakthrough has the potential to improve treatment outcomes for patients with cancer.
Researchers identify two genes, GLI1 and Notch1, responsible for aggressive growth and spread of triple negative breast cancers in African American women. A combination approach using inhibitors and chemotherapy agents significantly inhibits tumor growth and metastasis.
Researchers at Université catholique de Louvain have discovered a drug called MitoQ that prevents the appearance of metastases and local recurrences in human breast cancer. The molecule stops cancerous stem cells from awakening, offering a new treatment option for patients.
Researchers at UNIGE find that near-death experience in primary tumors triggers pro-metastatic states in cells, leading to metastasis. These 'PAME' cells reprogram themselves and trigger a cytokine storm, forming new tumors.
Melanoma skin cancer cells use Alzheimer's protein amyloid beta to survive in the brain, evading immune detection. A new study reveals a potential treatment target to counter this mechanism.
A study published in eLife reveals that cancer cells undergoing confined migration become more resistant to anoikis and exhibit increased invasiveness. This process may boost survival in cancer cells and make them more prone to forming deadly metastases.
Researchers have found that statins can inhibit the formation of tumors and metastases in animals with increased MACC1 expression. A study analyzing data from over 300,000 patients prescribed statins also showed a correlation between statin use and reduced cancer incidence.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
Researchers found that MYC inhibition by Omomyc exerts a dramatic effect on the metastatic process, reducing primary tumor and metastatic growth. The study suggests that MYC inhibition is anti-metastatic in breast cancer, offering promise as an anti-metastatic therapy.
Researchers have designed METPlatform, a drug screening platform compatible with patient biopsies, to investigate patients' own tumour tissue. The platform has identified new therapeutic targets and biomarkers for aggressive brain metastases, suggesting HSP90 inhibitors as potential treatments.
Researchers from National Cancer Centre Singapore have found a potential new strategy to treat peritoneal carcinomatosis, a metastatic form of intra-abdominal cancer. The team identified targeting ascites, excess fluid in the abdomen, as a way to remove fuel that drives cancer growth.
A new study highlights alternative treatment options that consider a patient's likelihood of recovery and quality of life. Total Definitive Treatment (TDT) is an approach that combines chemotherapy, radiation therapy, and close monitoring to potentially cure patients without surgery.
Researchers have discovered that p53 protein activates a molecular program turning damaged cells into migratory leader cells for quick epithelial repair. Once repaired, these highly migratory cells are eliminated to restore normal epithelial tissue structure.
A study found that chemotherapy can trigger cancer metastasis by altering lung tissue and creating a supportive environment for cancer cells. The researchers discovered that the LOX enzyme's increased secretion by immune cells can lead to this phenomenon, which is relevant to other drugs and cancers.
Scientists analyzed over 100,000 cells from 15 human brain metastases and identified two functional archetypes of metastatic cells, each containing both immune and non-immune cell types. These archetypes work together within single cells to shape inflammatory and proliferative processes co-existent in each metastatic tumor.
UCSF cancer biologist Hani Goodarzi is recognized for his groundbreaking research on cancer metastasis and novel molecular players. His work has led to the discovery of a protein driving breast cancer metastasis and orphan noncoding RNAs in cancerous cells.
Researchers at Children's Hospital of Philadelphia define a 3-tiered molecular classification system for pediatric differentiated thyroid cancer, where fusion oncogenes are associated with more invasive disease and lower remission rates. The study contrasts findings from adults, who have a two-tiered system based on BRAF mutations.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Melanoma cells release small packages containing the protein NGFR, which primes nearby lymph nodes to form new vessels and encourage cancer spread. This process, called lymphangiogenesis, may help doctors determine which patients need more aggressive treatment.
A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.
A study investigated the common use of extended radiation therapy for patients with metastatic cancer nearing the end of life. Despite guidelines advising against this practice, researchers found that it is still used in many cases. The study aims to shed light on this treatment approach and its implications for patient care.
A study published in Cell Metabolism reveals unique features of brain metastasis in breast cancers, highlighting potential new targets for therapies. Researchers found that metabolically distinct cells have varying levels of glucose and glutamine usage, which can be targeted to reduce metastatic activity.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
Researchers at Massachusetts General Hospital found that inhibiting the OR5B21 gene significantly decreased breast cancer metastasis to the brain, bones and lung. This discovery may lead to new therapeutic targets to prevent or delay breast cancer's spread.
Researchers have found that depleting copper levels in the body can greatly reduce the ability of cancer cells to metastasize, including aggressive breast cancer. The discovery provides hope for developing more effective treatments for high-risk triple-negative breast cancer.
A recent UCLA-led study provided indirect evidence that PSMA PET/CT improves risk-stratification and prognostic capabilities for high-risk prostate cancer patients. The study found that PSMA nomogram outperformed existing tools in predicting clinical outcomes, suggesting its significance in disease course prediction.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
A study published in eLife reveals that a small signalling protein called ARL4C is overexpressed in pancreatic cancer patients, facilitating their aggressive behavior. By inhibiting ARL4C, researchers have shown promise in reducing the spread of pancreatic cancer cells, opening up new therapeutic avenues.
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
Researchers have discovered a new therapeutic approach that prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state. The drug C26 activates NR2F1, a protein that can induce cancer cell dormancy and prevent recurrence and metastasis.
A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
Research reveals that cancer cells have softer membranes than normal cells, but stiffening them can prevent abnormal changes in structure and motility. Stiffened breast cancer cells lost the ability to spread to the lungs in mouse experiments, suggesting a potential strategy for cancer treatments.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
Children in UK and Ireland diagnosed with larger kidney cancers, leading to late diagnosis and potential poorer outcomes. A call for frontline healthcare workers to be trained in paediatric medicine has been made to improve early detection.
A study found that arginine treatment improved outcomes in cancer patients with brain metastases, showing a complete or partial response in nearly 78% of patients. The amino acid may be useful as an anticancer therapy when combined with radiotherapy or other treatments.
A study published in Nature Communications found that neuroendocrine tumors in the small intestine often originate from different cells with unique genetic mutations. This breakthrough challenges conventional wisdom on cancer development and highlights the importance of removing all detected tumors to prevent late relapses.
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
Researchers found that tumors with few micro-blood vessels are associated with defective perfusion, impacting the efficiency of systemic chemotherapy. This study highlights the importance of improving diagnostic imaging equipment to better detect lymph node metastasis and curb cancer-related mortality.
Researchers in mice found that chemotherapy enhances cancer's spread by making blood vessel walls more receptive, allowing cancer cells to latch on. The study shows how a chemo drug like cyclophosphamide alters non-cancer cells' properties, facilitating the cancer cells' attachment and progression.